
Biochemistry of Drug Metabolizing Enzymes
Trends and Challenges
- 1st Edition - May 28, 2022
- Imprint: Academic Press
- Editors: Muhammad Sajid Hamid Akash, Kanwal Rehman
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 5 1 2 0 - 3
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 5 1 2 1 - 0
Biochemistry of Drug Metabolizing Enzymes: Trends and Challenges is a complete and well-integrated reference on their mechanisms of action, their role in diseases, agents responsib… Read more

Purchase options

Institutional subscription on ScienceDirect
Request a sales quoteBiochemistry of Drug Metabolizing Enzymes: Trends and Challenges is a complete and well-integrated reference on their mechanisms of action, their role in diseases, agents responsible for their deactivation, and their malfunction. Chapters explain the biochemistry of DMEs, including biochemical activation, functions, computational approaches, different contaminants on the action and function of DMEs, and describe the importance of DMEs in the drug development process. Conditions covered include metabolic diseases, cardiovascular diseases, neurological diseases, physiological diseases, xenobiotics and inflammatory responses, and their contribution in the malfunctioning of drug metabolizing enzymes.
This book is the perfect resource for pharmacology and biochemistry researchers to understand the principles of DMEs. Researchers in the corporate environment will also benefit from the comprehensive list of diseases associated with malfunction of DMEs.
- Includes extensive classification of DMEs, their mechanism of action and computational analysis
- Covers the biotransformation of drug by DMEs and the possible impact of environmental contaminants
- Discusses the activity of DMEs in different clinical conditions such as cardiovascular disease, metabolic disorders, inflammation and neurotoxicity
- Includes modern and novel bioanalytical techniques to predict the effect of DMEs
Researchers and scientists in Pharmaceutical Sciences, Biochemistry and biotechnology. Drug development corporate researchers
- Cover
- Title page
- Table of Contents
- Copyright
- Contributors
- Chapter 1: Biochemical activation and functions of drug-metabolizing enzymes
- Abstract
- 1: Introduction
- 2: Phase I drug-metabolizing enzymes
- 3: Phase II drug-metabolizing enzymes
- 4: Phase III biotransformation reactions
- 5: Conclusion
- References
- Chapter 2: Computational approaches for drug-metabolizing enzymes: Concepts and challenges
- Abstract
- 1: Introduction
- 2: Metabolism in human body
- 3: Drug-metabolizing enzymes
- 4: Computational approaches
- 5: Data modeling
- 6: Databases
- 7: Softwares
- 8: Stereoselectivity
- 9: Regioselectivity
- 10: Inadequacies of current in silico method
- 11: Conclusion and future perspectives
- References
- Chapter 3: Role of drug-metabolizing enzymes in biotransformation of drugs
- Abstract
- 1: Introduction
- 2: Biotransformation reactions and drug metabolizing enzymes
- 3: Conclusion
- Conflict of interest
- References
- Chapter 4: Emerging environmental contaminants and drug-metabolizing enzymes
- Abstract
- 1: Introduction
- 2: Pharmaceuticals and personal care products
- 3: Plasticizers
- 4: Pesticides
- 5: Surfactants as emerging contaminants
- 6: Emerging environmental contaminants and their enzyme-assisted biodegradation
- 7: Mechanism and function of drug-metabolizing enzymes
- 8: EECs and drug-metabolizing enzymes induction
- 9: Conclusion
- References
- Chapter 5: Drug-metabolizing enzymes and fate of prodrugs: From function to regulation
- Abstract
- 1: Introduction
- 2: Prodrug
- 3: Biotransformation reactions
- 4: Drug-metabolizing enzymes
- 5: Conclusions
- References
- Chapter 6: Hormones and drug-metabolizing enzymes: From function to regulation
- Abstract
- 1: Introduction
- 2: Drug metabolism of metabolizing enzymes
- 3: Impact of hormones on drug-metabolizing enzymes
- 4: Physiological states and disorders causing hormonal changes
- 5: Conclusion
- References
- Chapter 7: Receptors and drug-metabolizing enzymes: From function to regulation
- Abstract
- 1: Introduction
- 2: Drug-metabolizing enzymes
- 3: Phase I biotransformation
- 4: Phase II biotransformation
- 5: Phase III biotransformation
- 6: Receptors and their functional impairment with DMEs
- 7: Regulation of DMEs biotransformation by xenobiotic receptors PXR and CAR
- 8: Receptors and their functional impairment with DMEs
- 9: Linking of xenobiotic NRs to drug interactions
- 10: Cross-talk between PXR and CAR
- 11: Conclusion remarks
- References
- Chapter 8: Biochemistry of cathepsins enzymes and their metabolic activity in the lysosome
- Abstract
- Acknowledgment
- 1: Introduction
- 2: Cathepsins in the lysosome
- 3: Cathepsins synthesis
- 4: M6P route for sorting and regulatory mechanisms
- 5: Secretion of cathepsins
- 6: Physiological function of cathepsins inside the lysosomes
- 7: Mediate drug metabolism
- 8: Pathophysiology of cathepsins
- 9: Conclusion
- References
- Chapter 9: Fate of drug-metabolizing enzymes in metabolic diseases
- Abstract
- 1: Introduction
- 2: Human drug-metabolizing CYP450 enzymes
- 3: Enzyme inhibition and induction
- 4: Factors affecting enzyme activity
- 5: Fate of drug metabolism in metabolic diseases
- 6: Challenges and strategies related to DMEs in metabolic disorder
- 7: Conclusion
- References
- Chapter 10: Fate of drug-metabolizing enzymes in cardiovascular diseases: Concepts and challenges
- Abstract
- 1: Introduction
- 2: Expression of phase I and phase II drug-metabolizing enzymes in cardiovascular system
- 3: Fate of CYP1B1 in cardiovascular pathology
- 4: Pharmacogenomics of cardiovascular diseases and cardiovascular drugs
- 5: Gender-specific variations of DMEs in pharmacotherapy of cardiovascular diseases
- 6: Conclusion
- References
- Chapter 11: Fate of drug-metabolizing enzymes in neurological diseases: Challenges and strategies
- Abstract
- 1: Introduction
- 2: CYP450 system and drug metabolism
- 3: Nomenclature of CYPs
- 4: Classification of CYPs
- 5: CYP450 and drug metabolism
- 6: Drug metabolizing enzymes in central nervous system
- 7: Implications of DME on neuropsychiatric diseases
- 8: CYPs and psychiatric diseases
- 9: Role of CYP450 in ischemic brain injury
- 10: Brain CYPs and drug addiction
- 11: Brain CYPP2D and chronic antidepressant therapy
- 12: Fate of cytochrome P450 in epilepsy
- 13: CYP-450 and Alzheimer’s disease
- 14: Pathological and clinical correlates of CYP450 in implications of Parkinson’s disease
- 15: Mutation spectrum in DME and its clinical manifestations
- 16: Current challenges and future perspective
- 17: Conclusion
- Conflict of interest
- Author contributions
- References
- Chapter 12: Impact of physiological factors on drug-metabolizing enzymes: From function to regulation
- Abstract
- 1: Introduction
- 2: Drug metabolism
- 3: Pathways of drug metabolism
- 4: Factors affecting drug metabolism
- 5: Physiological factors affecting drug metabolism
- 6: NADPH: CYP450 oxidoreductase (POR)
- 7: Conclusion
- Conflict of interest
- References
- Chapter 13: Xenobiotics and drug-metabolizing enzymes: Challenges and strategies
- Abstract
- 1: Introduction
- 2: Drug-metabolizing enzymes
- 3: Phases of drug-metabolizing enzymes
- 4: Types of drug-metabolizing enzymes
- 5: Xenobiotics metabolism
- 6: Gut microbiota and metabolic process of xenobiotics
- 7: Challenges
- 8: Factors affecting drug metabolism
- 9: Strategies
- 10: Conclusion
- References
- Chapter 14: Drug-metabolizing enzymes and inflammatory responses
- Abstract
- 1: Introduction
- 2: Gene expression and inflammatory processes
- 3: Regulation of DMEs in inflammatory disorders
- 4: Effect of inflammation on CYP regulation
- 5: Mechanism of CYPs regulation
- 6: Signaling pathways associated with CYP regulation
- 7: Regulation of mRNA expression of CYP enzymes
- 8: Role of CYPs in inflammatory responses
- 9: Regulation of phase II enzymes in inflammation
- 10: Conclusion
- References
- Chapter 15: Polymorphisms in drug-metabolizing enzymes: Challenges and strategies
- Abstract
- 1: Introduction
- 2: Evolution of pharmacogenomics
- 3: Interindividual drug responses
- 4: Genetic polymorphisms of DMEs
- 5: Polymorphisms in drug transporter genes
- 6: Polymorphisms of DMEs and their impact on drug-drug interactions
- 7: Strategies in pharmacogenomic research and development
- 8: Role of bioinformatics in pharmacogenomic research
- 9: From scientific evidence to clinical practice
- 10: Conclusion
- References
- Chapter 16: Modulation of human microbiome and drug metabolism
- Abstract
- 1: Introduction
- 2: Gut microbiota and drug pharmacokinetics
- 3: Modification of gut microbiota
- 4: Prospects
- References
- Chapter 17: Bioanalytical techniques for prediction of metabolic activity of drug-metabolizing enzymes
- Abstract
- 1: Introduction
- 2: Metabolomics approaches
- 3: Models for drug metabolism evaluation
- 4: Approaches for metabolite quantification
- 5: Bioanalytic techniques for metabolites identification
- 6: Other suitable approaches for metabolite identification
- 7: Conclusion
- References
- Chapter 18: Role of pharmacogenomics for prediction of personalized medicines
- Abstract
- 1: Introduction
- 2: Factor affecting the drug response
- 3: Pharmacogenomics biomarker
- 4: Tools that modify the risk prediction and risk assessment
- 5: Applications of pharmacogenomics and personalized medicine
- 6: Pharmacogenomics impact on personalized medicine
- 7: Conclusion
- References
- Chapter 19: Dietary sources of drug-metabolizing enzymes: From production to regulation
- Abstract
- 1: Introduction
- 2: Regulation of drug-metabolizing enzymes
- 3: Association of food products with regard to drug-metabolizing enzymatic action
- 4: Fruits interaction with metabolic enzymes
- 5: Vegetable interaction with metabolic enzymes
- 6: Common drug and nutrient interactions
- 7: Conclusion
- References
- Chapter 20: Vitamin deficiencies and drug-metabolizing enzymes: Challenges and strategies
- Abstract
- 1: Introduction
- 2: Impact of vitamin deficiencies on drug-metabolizing enzymes
- 3: Impact of vitamin deficiencies on drug metabolism
- 4: Conclusion
- References
- Chapter 21: Fate of drug-metabolizing enzymes in malnutrition: Challenges and strategies
- Abstract
- 1: Introduction
- 2: Drug metabolism
- 3: Protein calorie malnutrition
- 4: Effect of low carbohydrate diet on drug-metabolizing enzymes
- 5: Effect of fat-free diet on drug-metabolizing enzymes
- 6: Effect of mineral deficiency on drug-metabolizing enzymes
- 7: Effect of vitamin deficiency on drug-metabolizing enzymes
- 8: Effect of iron deficiency on drug-metabolizing enzymes
- 9: Conclusion
- References
- Chapter 22: Drug-metabolizing enzymes and oxidative stress
- Abstract
- 1: Introduction
- 2: Generation of reactive oxygen species during drug metabolism
- 3: Oxidative stress generated by drug metabolites
- 4: Endogenous defense against oxidative stress
- 5: Antioxidant therapy
- 6: Conclusion
- References
- Index
- Edition: 1
- Published: May 28, 2022
- No. of pages (Paperback): 586
- No. of pages (eBook): 586
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780323951203
- eBook ISBN: 9780323951210
MA
Muhammad Sajid Hamid Akash
KR